Daiwa Securities Group’s Adverum Biotechnologies ADVM Stock Holding History

Daiwa Securities Group’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18	Closed	–	–	1310
2022 Q3	$0	Hold	18	–	–	﹤0.01%	1330
2022 Q2	$0	Hold	18	–	–	﹤0.01%	1345
2022 Q1	$0	Hold	18	–	–	﹤0.01%	1371
2021 Q4	$0	Hold	18	–	–	﹤0.01%	1385
2021 Q3	$0	Hold	18	–	–	﹤0.01%	1310
2021 Q2	$1K	Hold	18	–	–	﹤0.01%	1175
2021 Q1	$2K	Hold	18	–	–	﹤0.01%	1131
2020 Q4	$2K	Sell	18 -26	-59%	-$3.22K	﹤0.01%	1106
2020 Q3	$5K	Hold	44	–	–	﹤0.01%	1083
2020 Q2	$4K	Hold	44	–	–	﹤0.01%	1114
2020 Q1	$4K	Buy	44 +7	+19%	+$816	﹤0.01%	1110
2019 Q4	$4K	Sell	37 -4	-10%	-$353	﹤0.01%	1118
2019 Q3	$2K	Hold	41	–	–	﹤0.01%	1120
2019 Q2	$5K	Hold	41	–	–	﹤0.01%	1095
2019 Q1	$2K	Buy	+41	New	+$1.66K	﹤0.01%	1124

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Daiwa Securities Group's ADVM Position: Q4 2022 in Review

Daiwa Securities Group sold out of Adverum Biotechnologies (ADVM) in Q4 2022, closing a stake of 18 shares.

Daiwa Securities Group first reported a position in ADVM in Q1 2019 and held it in 15 quarters. The position peaked at $5K in Q3 2020. 59 funds tracked by Wall St. Rank hold ADVM as of Q4 2022.

Daiwa Securities Group reported no remaining Adverum Biotechnologies position as of Q4 2022 after selling out during the quarter.
Daiwa Securities Group sold 18 Adverum Biotechnologies shares in Q4 2022.
Daiwa Securities Group first reported a position in Adverum Biotechnologies in Q1 2019 and held it in 15 quarters.
Daiwa Securities Group's Adverum Biotechnologies position peaked at $5K in Q3 2020.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.